AI filing briefs · archive

8-K filings in September 2026, explained

1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

2 of 1,853 briefs match

newest first · times in ET

AINALBANY INTERNATIONAL CORP /DE/ Sep 1, 4:37 PM ET

Albany International retains Salt Lake City facility, raises Q3 adjusted EPS outlook

Positive guidance Written later 2.02 7.01

Albany International said it completed its strategic review of the Amelia Earhart Drive facility in Salt Lake City and will keep the site, following an amended CH-53K contract with Sikorsky and new business wins. The company also reversed part of a forward loss reserve from the third quarter of 2025 and raised its third-quarter 2026 adjusted EPS outlook to $1.40 to $1.50, while its net revenue outlook was unchanged.

The company will retain the Amelia Earhart Drive facility and end the strategic review; Guggenheim Securities served as its financial advisor.
It reversed a portion of the forward loss reserve recognized in Q3 2025 on the CH-53K contract, and the contract modification is expected to generate positive cash flow beginning in 2027.
Q3 2026 adjusted EPS outlook rose from $0.60 to $0.70 to $1.40 to $1.50; Q3 consolidated net revenue outlook remains $320 million to $330 million.
Q4 2026 outlook calls for consolidated net revenue of $325 million to $335 million and adjusted EPS of $0.65 to $0.75; investor webcast on September 2, 2026 at 8:30 a.m. ET.

Read the filing on SEC.gov ↗

MDTMedtronic plc Sep 1, 6:47 AM ET

Medtronic Q1 revenue rises 13.7% to $9.8 billion and raises fiscal 2027 guidance

Positive guidance Written later 2.02

Medtronic reported first quarter fiscal 2027 revenue of $9.8 billion, up 13.7% as reported and organically, and GAAP diluted EPS of $1.14 versus $0.81 a year earlier. The company raised its fiscal 2027 organic revenue growth guidance to 7.25% to 7.75% and its non-GAAP diluted EPS guidance to $5.94 to $6.00, both measures improving on the prior outlook.

Q1 revenue of $9.756 billion, up 13.7% as reported and organically; the extra fiscal week benefited organic growth by approximately $570 million, per the company
Q1 GAAP diluted EPS of $1.14, up 40.7%; non-GAAP diluted EPS of $1.45, up 15.1%
FY27 organic revenue growth guidance raised to 7.25% to 7.75% from 6.75% to 7.25%
FY27 non-GAAP diluted EPS guidance raised to $5.94 to $6.00 from $5.90 to $6.00

Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.